Targeting ST3GAL3-AS1: A Potential Drug Target and Biomarker (G101929592)

Target Name: ST3GAL3-AS1

NCBI ID: G101929592

ST3GAL3-AS1

Other Name(s): ST3GAL3 antisense RNA 1

Targeting ST3GAL3-AS1: A Potential Drug Target and Biomarker

Staurolactan III (ST3) is a family of structurally unique non-coding RNAs (ncRNAs) that plays a pivotal role in various cellular processes, including cell signaling, DNA replication, and repair, among others. ST3 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the promising leads from this family is ST3GAL3-AS1 (ST3GAL3 antisense RNA 1), which is a non-coding RNA produced by the ST3 gene and has been shown to play a critical role in the regulation of ST3 expression. In this article, we will explore the potential of ST3GAL3-AS1 as a drug target and biomarker.

Structure and Function

The ST3 gene is located on chromosome 16p36 and encodes a non-coding RNA molecule with a unique structure and function. The ST3 RNA has a single exon and consists of a 130-nt primary RNA molecule that is annotated as a stem-loop RNA. The stem-loop region of ST3 RNA is the most conserved and is responsible for the formation of a stem-loop structure, which is a common feature of many RNA molecules. The loops in the stem-loop region interact with various protein partners, including the ST3 protein, to regulate the expression of the ST3 gene.

ST3GAL3-AS1 is a non-coding RNA produced by the ST3 gene that has been shown to play a critical role in the regulation of ST3 expression. The RNA has a unique structure and is composed of a single exon that is highly conserved with ST3. The 5' end of the RNA contains a termination codon, which is responsible for the cessation of transcription, while the 3' end contains a stem-loop structure that is similar to that of ST3 RNA.

Expression and Function

ST3GAL3-AS1 is highly expressed in various tissues and cells, including human brain, heart, and cancer cells. In addition, the RNA has been shown to play a critical role in the regulation of ST3 expression, which is a known function of ST3GAL3-AS1. Specifically, the RNA has been shown to bind to the ST3 protein and prevent it from being translated into a functional protein. This interaction between ST3GAL3-AS1 and ST3 protein suggests that the RNA may have a negative regulatory role on ST3 expression.

Furthermore, ST3GAL3-AS1 has been shown to play a critical role in the regulation of cellular processes, including cell signaling, DNA replication, and repair. For instance, the RNA has been shown to play a role in the regulation of cell cycle progression, which is a critical process that controls the growth and division of cells. Additionally, the RNA has been shown to play a role in the regulation of DNA replication, which is a critical process that ensures the genetic integrity of the cell.

Drug Target Potential

The potential drug target for ST3GAL3-AS1 is based on its role in the regulation of ST3 expression and its involvement in various cellular processes. Several studies have shown that inhibitors of ST3GAL3-AS1 have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For instance, a small molecule inhibitor, ST3-AS1, has been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, a monoclonal antibody targeting ST3GAL3-AS1 has been shown to be effective in treating

Protein Name: ST3GAL3 Antisense RNA 1

The "ST3GAL3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST3GAL3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets